Pharmacological interventions for antisocial personality disorder

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2009, Pages

  Khalifa, Najat ^a   Duggan, Conor ^b   Stoffers, Jutta M ^c   Huband, Nick ^a   Völlm, Birgit A ^a   Lieb, Klaus ^d   Ferriter, Michael ^e  

^a Section of Forensic Mental Health   (United Kingdom)

^b Division of Psychiatry   (United Kingdom)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^e RAMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BARBITURIC ACID DERIVATIVE; CENTRAL STIMULANT AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HYPNOTIC AGENT; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRANQUILIZER; TRICYCLIC ANTIDEPRESSANT AGENT;

AGGRESSION; ANGER; ATTENTION DEFICIT DISORDER; CINAHL; CLINICAL TRIAL; COCHRANE LIBRARY; DELINQUENCY; ECONOMIC ASPECT; EMBASE; EMPLOYMENT; HOUSING; HUMAN; IMPULSIVENESS; LEARNING DISORDER; MEDLINE; MENTAL HEALTH SERVICE; META ANALYSIS; PATIENT SATISFACTION; PSYCHOPATHY; PSYCINFO; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCISEARCH; SOCIAL INTERACTION; SUBSTANCE ABUSE; SYSTEMATIC REVIEW;

EID: 70249121016     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007667     Document Type: Review

References (52)

1. Altman DG, Bland JM. Detecting skewedness from summary information. BritishMedical Journal 1996;313(7066):1200.
2. American Psychiatric Association. Diagnostic and Statistical Manual ofMental Disorders (DSM-IV). 4th Edition. Washington DC: American Psychiatric Association, 1994.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders -Text Revision (DSM-IV-TR). Washington DC: American Psychiatric Association, 2000.
4. Attkisson CC, Zwick R. The client satisfaction questionnaire. Psychometric properties and correlations with service utilization and psychotherapy outcome. Evaluation and Program Planning 1982;5: 233-237
5. Black DW, Baumgard CH, Bell SE, Kao C. Death rates in 71 men with antisocial personality disorder: A comparison with general population mortality. Psychosomatics 1996;37(2):131-136 (Pubitemid 26066258)
6. Bond AJ. The neuropsychopharmacology of aggression and addiction. European Journal of Pharmacology 2005;526(1-3):218-225
7. Buss AH, Perry M. The Aggression Questionnaire. Journal of Personality and Social Psychology 1992;63:452-459
8. Coccaro EF, Kavoussi RJ, Sheline YI, Lish JD, CsernanskyG. Impulsive aggression in personality disorder correlates with tritiated paroxetine binding in the platelet. Archives of General Psychiatry 1996;53: 531-536
9. Coccaro EF, Kavoussi RJ, Hauger RL, Cooper TB, Ferris CF. Cerebrospinal fluid vasopressin levels: correlates with aggression and serotonin function in personality-disordered subjects. Archives of General Psychiatry 1998;55:708-714
10. Coid J, Yang M, Tyrer P, Roberts A, Ullrich S. Prevalence and correlates of personality disorder in Great Britain. British Journal of Psychiatry 2006;188:423-431
11. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine and tranylcypromin. Archives of General Psychiatry 1989;45:111-119
12. Dolan B, Coid J. Psychopathic and anti-social personality disorders: treatment and research Issues. London: Gaskell, 1993.
13. Donner A, Piaggio G, Villar J. Statistical methods for the metaanalysis of cluster randomization trials. StatisticalMethods inMedical Research 2001;10(5):325-338 (Pubitemid 33009365)
14. Duke PJ, Pantelis C, Barnes TRE. South Westminster Schizophrenia Survey. Alcohol use and its relationship to symptoms, tardive dyskinesia and illness onset. British Journal of Psychiatry 1994;164: 630-636. (Pubitemid 24161261)
15. Egger M, Davey-Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. British Medical Journal 1997;315:629-634 (Pubitemid 27387172)
16. Elbourne DR, Altman DG, Higgins JP, Curtin F,Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-149 (Pubitemid 34284916)
17. EuroQoL Group. EuroQoL: a new facility for measurement of health-related quality of life. Health Policy 1990;16:199-208.
18. Follmann D, Elliot P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. Journal of Clinical Epidemiology 1992;45(7):769-773
19. Gamble C, Hollis S. Uncertainty method on best-worst case analysis in a binary meta-analysis. Journal of Clinical Epidemiology 2005;58 (6):579-588 (Pubitemid 40692723)
20. Grilo CM, McGlashan TH, Oldham JM. Course and stability of personality disorders. Journal of Practical Psychiatry and Behavioural Health 1998;4:61-75.
21. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 5.0.0. www.cochrane.org/resources/handbook/hbook.htm (accessed 1 April 2008).
22. Home Office and Department ofHealth. Managing peoplewith severe personality disorder. London: Home Office, 1999.
23. Huband N, McMurran M, Evans C, Duggan C. Social problemsolving plus psychoeducation for adults with personality disorder: pragmatic randomised controlled trial. British Journal of Psychiatry 2007;190:307-313 (Pubitemid 46580679)
24. Links P. Lithiumtherapy for borderline patients. Journal of Personality Disorders 1990;4:173-181
25. Malone RP, Luebbert RP, Pena-Ariet M, Biesecker K, Delaney MA. The Overt Aggression Scale in the study of lithium in aggressive conduct disorder. Psychopharmacology Bulletin 1994;30:215-218 (Pubitemid 24331390)
26. Markovitz PJ. Recent trends in the pharmacotherapy of personality disorders. Journal of Personality Disorders 2004;18(1):90-101. (Pubitemid 38338012)
27. Moran P. The epidemiology of antisocial personality disorder. Social Psychiatry and Psychiatric Epidemiology 1999;34(5):231-242
28. Myers MG, Stewart DG, Brown SA. Progression from conduct disorder to antisocial personality disorder following treatment for adolescent substance abuse. American Journal of Psychiatry 1998;155: 479-485.
29. Newton-Howes G, Tyrer P, Johnson T. Personality disorder and the outcome of depression: meta-analysis of published studies. British Journal of Psychiatry 2006;188:13-20. (Pubitemid 43021921)
30. Paris J. Personality Disorders Over Time: Precursors, Course, and Outcome. Arlington, Va: American Psychiatric Publishing, 2003.
31. Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt impulsiveness scale. Journal of Clinical Psychology 1995;51(6):768-774
32. Raine A, Lencz T, Bihrle S, LaCasse L, Colletti P. Reduced prefrontal gray matter volume and reduced autonomic activity in antisocial personality disorder. Archives of General Psychiatry 2000;57:119-127. (Pubitemid 30075261)
33. Reed J. Working Group on Psychopathic Disorder: Report (Chairman Dr John Reed). London: Department of Health, 1994.
34. Robins LN, Tipp J, Przybeck T. Antisocial personality. In: Robins LN, Regier DA editor(s). Psychiatric disorders in America. New York: Free Press, 1991.
35. Scott S, KnappM,Henderson J,Maughan B. Financial cost of social exclusion: follow up study of antisocial children into adulthood. British Medical Journal 2001;323:191-195
36. Singleton N,Melzer H,Gatward R. Psychiatricmorbidity among prisoners in England and Wales. London: HM Stationery Office, 1998.
37. Skodol AE, Siever LJ, Livesley WJ, Gunderson JG, Pfohl B,Widiger TA. The borderline diagnosis II: biology, genetics and clinical course. Biological Psychiatry 2002;51:951-963 (Pubitemid 34607711)
38. Skodol AE,Oldham JM, Bender DS, Dyck IR, Stout RL,Morey LC, et al.Dimensional representations of DSM-IV personality disorders: relationships to functional impairment. American Journal of Psychiatry 2005;162(10):1919-1925 (Pubitemid 41428622)
39. Soloff PH. Algorithms for pharmacological treatment of personality dimensions. Symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioral dysregulation. Bulletin of the Menninger Clinic 1998;62:195-214.
40. Spielberger CD. STAXI-2: State-Trait Anger Expression Inventory-2. Odessa, FL: Psychological Assessment Resources, Inc., 1999.
41. SteinGS.Drug treatment of the personality disorders. British Journal of Psychiatry 1992;161:167-184
42. Stein DJ, Simeon D, Frenkel M, Islan MN, Hollander E. An open trial of valproate in borderline personality disorder. Journal ofClinical Psychiatry 1995;56:506-510
43. Sugden SG, Kile SJ, Hendren R. Neurodevelopmental pathways to aggression: a model to understand and target treatment in youth. Journal of Neuropsychiatry and Clinical Neurosciences 2006;18(3): 302-317
44. SwansonMC, Bland RC, Newman SC. Epidemiology of psychiatric disorders in Edmonton: antisocial personality disorders. Acta Psychiatrica Scandinavica. Supplementum 1994;376:63-70.
45. Tait L, Birchwood M, Trower P. A new scale (SES) to measure engagement with community mental health services. Journal ofMental Health 2002;11(1):191-198 (Pubitemid 34496793)
46. Torgensen S, Kringlen E, Cramer V. The prevalence of personality disorders in a community sample. Archives ofGeneral Psychiatry 2001; 58:590-596 (Pubitemid 32523740)
47. Tyrer P, Bateman AW. Drug treatment for personality disorders. Advances in Psychiatric Treatment 2004;10:389-398
48. Tyrer P,NurU,CrawfordM. The Social Functioning Questionniare: a rapid and robust measure of perceived functioning. International Journal of Social Psychiatry 2005;51:265-275
49. Warren F, Preedy-Fayers K, McGauley G, Pickering A, Norton K, Geddes JR, et al.Review of treatments for severe personality disorder. London: Home Office, 2001.
50. Weissman MM, Bothwell S. Assessment of social adjustment by patient self-report. Archives of General Psychiatry 1976;33:1111-1115
51. Weissman MM. The epidemiology of personality disorders: a 1990 update. Journal of Personality Disorders 1993;Suppl.:44-62.
52. Wilcox JA. Divalproex sodium as a treatment for borderline personality disorder. Annals of Clinical Psychiatry 1995;7(1):33-37